Cardiac autonomic imaging with SPECT tracers

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Radionuclide cardiac imaging has potential to assess underlying molecular, electrophysiologic, and pathophysiologic processes of cardiac disease. An area of current interest is cardiac autonomic innervation imaging with a radiotracer such as 123I-meta-iodobenzylguanidine (123I-mIBG), a norepinephrine analogue. Cardiac 123I-mIBG uptake can be assessed by planar and SPECT techniques, involving determination of global uptake by a heart-to-mediastinal ratio, tracer washout between early and delayed images, and focal defects on tomographic images. Cardiac 123I-mIBG findings have consistently been shown to correlate strongly with heart failure severity, pre-disposition to cardiac arrhythmias, and poor prognosis independent of conventional clinical, laboratory, and image parameters. 123I-mIBG imaging promises to help monitor a patient's clinical course and response to therapy, showing potential to help select patients for an ICD and other advanced therapies better than current methods. Autonomic imaging also appears to help diagnose ischemic heart disease and identify higher risk, as well as risk-stratify patients with diabetes. Although more investigations in larger populations are needed to strengthen prior findings and influence modifications of clinical guidelines, cardiac 123I-mIBG imaging shows promise as an emerging technique for recognizing and following potentially life-threatening conditions, as well as improving our understanding of the pathophysiology of various diseases.

Original languageEnglish (US)
Pages (from-to)128-143
Number of pages16
JournalJournal of Nuclear Cardiology
Volume20
Issue number1
DOIs
StatePublished - Feb 2013

Fingerprint

3-Iodobenzylguanidine
Single-Photon Emission-Computed Tomography
Radionuclide Imaging
Myocardial Ischemia
Cardiac Arrhythmias
Heart Diseases
Norepinephrine
Heart Failure
Guidelines
Therapeutics
Population

Keywords

  • autonomic imaging
  • iodine-123
  • MIBG imaging
  • molecular imaging

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Cardiac autonomic imaging with SPECT tracers. / Travin, Mark I.

In: Journal of Nuclear Cardiology, Vol. 20, No. 1, 02.2013, p. 128-143.

Research output: Contribution to journalArticle

@article{b8a8cda50ba748e1bbbe9431cb3c93df,
title = "Cardiac autonomic imaging with SPECT tracers",
abstract = "Radionuclide cardiac imaging has potential to assess underlying molecular, electrophysiologic, and pathophysiologic processes of cardiac disease. An area of current interest is cardiac autonomic innervation imaging with a radiotracer such as 123I-meta-iodobenzylguanidine (123I-mIBG), a norepinephrine analogue. Cardiac 123I-mIBG uptake can be assessed by planar and SPECT techniques, involving determination of global uptake by a heart-to-mediastinal ratio, tracer washout between early and delayed images, and focal defects on tomographic images. Cardiac 123I-mIBG findings have consistently been shown to correlate strongly with heart failure severity, pre-disposition to cardiac arrhythmias, and poor prognosis independent of conventional clinical, laboratory, and image parameters. 123I-mIBG imaging promises to help monitor a patient's clinical course and response to therapy, showing potential to help select patients for an ICD and other advanced therapies better than current methods. Autonomic imaging also appears to help diagnose ischemic heart disease and identify higher risk, as well as risk-stratify patients with diabetes. Although more investigations in larger populations are needed to strengthen prior findings and influence modifications of clinical guidelines, cardiac 123I-mIBG imaging shows promise as an emerging technique for recognizing and following potentially life-threatening conditions, as well as improving our understanding of the pathophysiology of various diseases.",
keywords = "autonomic imaging, iodine-123, MIBG imaging, molecular imaging",
author = "Travin, {Mark I.}",
year = "2013",
month = "2",
doi = "10.1007/s12350-012-9655-1",
language = "English (US)",
volume = "20",
pages = "128--143",
journal = "Journal of Nuclear Cardiology",
issn = "1071-3581",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Cardiac autonomic imaging with SPECT tracers

AU - Travin, Mark I.

PY - 2013/2

Y1 - 2013/2

N2 - Radionuclide cardiac imaging has potential to assess underlying molecular, electrophysiologic, and pathophysiologic processes of cardiac disease. An area of current interest is cardiac autonomic innervation imaging with a radiotracer such as 123I-meta-iodobenzylguanidine (123I-mIBG), a norepinephrine analogue. Cardiac 123I-mIBG uptake can be assessed by planar and SPECT techniques, involving determination of global uptake by a heart-to-mediastinal ratio, tracer washout between early and delayed images, and focal defects on tomographic images. Cardiac 123I-mIBG findings have consistently been shown to correlate strongly with heart failure severity, pre-disposition to cardiac arrhythmias, and poor prognosis independent of conventional clinical, laboratory, and image parameters. 123I-mIBG imaging promises to help monitor a patient's clinical course and response to therapy, showing potential to help select patients for an ICD and other advanced therapies better than current methods. Autonomic imaging also appears to help diagnose ischemic heart disease and identify higher risk, as well as risk-stratify patients with diabetes. Although more investigations in larger populations are needed to strengthen prior findings and influence modifications of clinical guidelines, cardiac 123I-mIBG imaging shows promise as an emerging technique for recognizing and following potentially life-threatening conditions, as well as improving our understanding of the pathophysiology of various diseases.

AB - Radionuclide cardiac imaging has potential to assess underlying molecular, electrophysiologic, and pathophysiologic processes of cardiac disease. An area of current interest is cardiac autonomic innervation imaging with a radiotracer such as 123I-meta-iodobenzylguanidine (123I-mIBG), a norepinephrine analogue. Cardiac 123I-mIBG uptake can be assessed by planar and SPECT techniques, involving determination of global uptake by a heart-to-mediastinal ratio, tracer washout between early and delayed images, and focal defects on tomographic images. Cardiac 123I-mIBG findings have consistently been shown to correlate strongly with heart failure severity, pre-disposition to cardiac arrhythmias, and poor prognosis independent of conventional clinical, laboratory, and image parameters. 123I-mIBG imaging promises to help monitor a patient's clinical course and response to therapy, showing potential to help select patients for an ICD and other advanced therapies better than current methods. Autonomic imaging also appears to help diagnose ischemic heart disease and identify higher risk, as well as risk-stratify patients with diabetes. Although more investigations in larger populations are needed to strengthen prior findings and influence modifications of clinical guidelines, cardiac 123I-mIBG imaging shows promise as an emerging technique for recognizing and following potentially life-threatening conditions, as well as improving our understanding of the pathophysiology of various diseases.

KW - autonomic imaging

KW - iodine-123

KW - MIBG imaging

KW - molecular imaging

UR - http://www.scopus.com/inward/record.url?scp=84872684762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872684762&partnerID=8YFLogxK

U2 - 10.1007/s12350-012-9655-1

DO - 10.1007/s12350-012-9655-1

M3 - Article

C2 - 23188628

AN - SCOPUS:84872684762

VL - 20

SP - 128

EP - 143

JO - Journal of Nuclear Cardiology

JF - Journal of Nuclear Cardiology

SN - 1071-3581

IS - 1

ER -